SCHEMBL4421533

SCHEMBL4421533

COc1cc(CN2CC3C(C2)C3C(=O)Nc2ccc(N3CCOCC3)c(F)c2)cc(OC)c1OC

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MTOR P42345 2/20 0.49
LMNA P02545 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
KDM4E B2RXH2 2/20 0.44
HTT P42858 2/20 0.44
MAPT P10636 4/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
LDHA P00338 1/20 0.44
LDHB P07195 1/20 0.44
KMT2A Q03164 1/20 0.43
ALDH1A1 P00352 2/20 0.42
ALDH2 P05091 1/20 0.42
TP53 P04637 1/20 0.42
THRB P10828 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
NPY2R P49146 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4415238 0.88 HIF1A (0.52) MTORLMNAL3MBTL1KDM4EHTT
SCHEMBL4425283 0.86 MAPT (0.48) MTORLMNAL3MBTL1KDM4EHTT
SCHEMBL2170675 0.85 L3MBTL1 (0.52) MTORLMNAL3MBTL1KDM4EHTT
SCHEMBL4412368 0.85 MAPT (0.53) MTORLMNAL3MBTL1KDM4EHTT
SCHEMBL4417594 0.84 L3MBTL1 (0.48) MTORLMNAL3MBTL1HTTMAPT
SCHEMBL4423641 0.83 NPC1 (0.49) MTORLMNAL3MBTL1HTTMAPT
SCHEMBL4421535 0.83 ALDH2 (0.43) MTORLMNAL3MBTL1KDM4EMAPT
SCHEMBL4423905 0.83 HTT (0.60) MTORLMNAL3MBTL1HTTMAPT
SCHEMBL4425268 0.83 L3MBTL1 (0.48) MTORLMNAL3MBTL1KDM4EHTT
SCHEMBL4423761 0.83 MTOR (0.49) MTORLMNAL3MBTL1HTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP claimed
EP-1680124-A4 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2009-05-13 EP claimed
JP-2007508374-A 2007-04-05 JP claimed
EP-1680124-A2 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS Pfizer Products Incorporated (US) 2006-07-19 EP claimed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US claimed
WO-2005037216-A2 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PRODUCTS INC. (US) 2005-04-28 WO claimed
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP disclosed
US-7473787-B2 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC (US) 2009-01-06 US disclosed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors SLC6A5, SLC1A5, SLC6A3 MTOR 1652/4885LMNA 4565/4885L3MBTL1 1416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.